-
Drug prevents bone loss in prostate cancer - Amgen
Jul 15, 08 Clinical UpdatesAmgen Inc on Monday said that a trial of its experimental drug denosumab showed that it can prevent osteoporosis in men being treated with prostate cancer drugs that can cause bone loss.
The three-year study of more than 1,400 men with non-metastatic prostate cancer undergoing androgen deprivation therapy showed denosumab produced greater increases in bone mineral density at the lumbar spine and non-vertebral sites than a placebo.
Men receiving denosumab also experienced less than half the incidence of new vertebral fractures than those receiving the placebo, Amgen said.
Both findings were statistically significant, it said.
CHICAGO (Reuters)
Also in this section:
Subscribe to the "News" RSS Feed 
TOP ۞
